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Carvedilol is a nonselective beta blocker/alpha-1 blocker, which is used for 
treatment of essential hypertension, chronic stable angina, unstable angina and ischemic 
left ventricular dysfunction. The aim of this study was to describe carvedilol population 
pharmacokinetic (PK) analysis as well as the validation of analytical procedure, which is 
an important step regarding this approach. In contemporary clinical practice, population 
PK analysis is often more important than standard PK approach in setting a 
mathematical model that describes the PK parameters. Also, it includes the variables 
that have particular importance in the drugs pharmacokinetics such as sex, body mass, 
dosage, pharmaceutical form, pathophysiological state, disease associated with the 
organism or the presence of a specific polymorphism in the isoenzyme important for 
biotransformation of the drug. One of the most frequently used approach in population 
PK analysis is the Nonlinear Modeling of Mixed Effects - NONMEM modeling. Analytical 
methods used in the data collection period is of great importance for the implementation 
of a population PK analysis of carvedilol in order to obtain reliable data that can be 
useful in clinical practice. High performance liquid chromatography (HPLC) analysis of 
carvedilol is used to confirm the identity of a drug and provide quantitative results and 
also to monitor the efficacy of the therapy. Analytical procedures used in other studies 
could not be fully implemented in our research as it was necessary to perform certain 
modification and validation of the method with the aim of using the obtained results for 
the purpose of a population pharmacokinetic analysis. Validation process is a logical 
terminal phase of analytical procedure development that provides applicability of the 
procedure itself. The goal of validation is to ensure consistency of the method and 
accuracy of results or to confirm the selection of analytical method for a given sample 
and drug. This study confirmed the importance of using valid analytical procedure for 
the purpose of carvedilol population pharmacokinetic analysis. Identification of 
demographic, pathophysiological and other factors that may influence the population 
carvedilol PK parameters gives the physician the possibility of a more comprehensive 
overview of the patient and better optimization of the therapeutical regimen. Acta 
Medica Medianae 2013;52(3):18-24.  
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Introduction 
 
In the recent years, the use of β-blockers 
(especially for uncomplicated hypertension) has 
been widely debated. Carvedilol is a nonselective 
beta blocker/alpha-1 blocker, who expresses 
vasodilatator effects (1). It binds to the receptors, 
inhibits their action and causes the blood vessels 
dilatation. Additionally, carvedilol is a potent 
antioxidant and anti-proliferative agent. Carvedilol 
reduces the peripheral vascular resistance through 
vasodilatation and blocking the renin-angiotensin-
aldosterone system. Carvedilol decreases blood 
pressure as well as heart rate, while the renal 
blood flow and renal function are preserved in 
patients with arterial hypertension. Cold extremities, 
which is often an adverse effect of the beta – 
blockers, are rare during carvedilol usage due to 
preserved blood flow through the extremities as 
w e l l  ( 2 ) .  I t  i s  u s e d  t o  t r e a t  e s s e n t i a l  h y p e r -
tension, chronic stable angina, unstable angina 
and ischemic left ventricular dysfunction. Carvedilol 
is used to treat congestive heart failure as it 
leads to reduction in mortality, rate of 
hospitalization, and improvement of disease 
progression. Possible side effects that could be 
expressed during carvedilol treatment include 
blurred vision, headaches, fatigue, brady-cardia, 
postural hypotension, hypotension, edema, nausea, 
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weight gain, hypercholesterolemia, asthma and 
dyspnea in patients with a predisposition, pain in 
the extremities and decreased lacrimation. 
Chemically, carvedilol is a racemic mixture 
of S and R enantiomers, of which the S 
enantiomer is responsible for the blockade of 
beta receptors (3). Carvedilol is characterized by 
distinct lipophilicity, which underlies the rapid 
absorption from the gastrointestinal tract. Maximum 
plasma concentration of carvedilol is being 
achieved in 1-2 hr after oral drug administration. 
It shows high rate of first-pass metabolism and 
high percentage of plasma proteins binding as 
well. It is a substrate for microsomal liver 
isoenzymes, especially cytochrome P450 2D6 
(CYP 2D6), but cytochrome P450 2C9 (CYP 2C9), 
3A4 (CYP 3A4), 1A2 (CYP 1A2), 2C19 (CYP 2C19) 
and 2E1 (CYP 2E1) are also involved in the 
biotransformation of carvedilol (3). Elimination 
half-life is 6 to 10 hours, which allows dosing 
every 12 hours. Participation of CYP 2D6 in the 
metabolism of carvedilol causes a large inter-
individual variability in the pharmacokinetics 
(PKs) and pharmacodynamics (PDs) of drug due 
to expressed polymorphism. CYP 2D6 enzyme 
gene polymorphism implies the existence of fast 
and slow metabolizers, which may determine 
variability in carvedilol clearance. This could lead 
to adverse drug effects or lack in efficiency after 
the application of the usual dose. 
Analytical methods need to be modified and 
validated in order to be used in other studies of 
the PK population. The goal of validation is to 
ensure consistency of the method and accuracy 
of results or to confirm the selection of analytical 
method for a given sample and drug (4). The 
main criteria are that the analytical method 
should meet are accuracy and precision (5). 
Validation process is a logical terminal phase of 
analytical procedure development that provides 
applicability of the procedure itself. Revalidation is 
always done when the existing methods is going 
to be used in other laboratory or when changes 
occur in the analytical procedure or the 
substance itself.  
Accordingly, for the investigation of the 
pharmacokinetics of carvedilol, we have developed 
a simple, sensitive method for its determination 
in human plasma. Regarding the period of the 
data collection for the population PK analysis, the 
total number of data that need to be processed 
and the complexity of population PK analysis 
procedure itself, it is necessary to validate the 
analytical procedure for carvedilol determination 
due to correct interpretation of the analysis 
results. Therefore, the aim of this study was to 
describe carvedilol population pharmaco-kinetic 
analysis as well as the validation of analytical 
procedure for its determination in human plasma 
samples. 
 
Previous studies on carvedilol HPLC 
determination 
 
High performance liquid chromatography 
(HPLC) is most frequently used for carvedilol 
determination in human plasma samples. This 
analytical method has also significant use in PK 
studies (6). For instance, PK studies of carvedilol 
after administration of buccal patch in pigs also 
applied the HPLC analysis. In this study, carvedilol 
and internal standard (Flecainide acetate) were 
extracted into n-hexane-dichloromethane solvent 
system and separated using an isocratic mobile 
phase on a Phenomenex C (18) column (7). The 
mobile phase consists of acetonitrile, methanol, 
water, and triethylamine at a ratio of 25:20: 
54.9:0.1 (v/v). The eluent was monitored by 
spectroflourimetric detector at a flow rate of 1.0 
mL/min. The pH was adjusted to 2.5 with 
orthophosphoric acid. Ptacek et al. introduced the 
HPLC method as simple and highly sensitive, 
based on protein precipitation with methanol and 
concentration of the supernatant by evaporation 
and reversed - phase chromatography with 
fluorimetric detection (8). The separation was 
performed on a Develosil 3 mm ODS 10034.6 
mm I.D. column and the mobile phase consisted 
of acetonitrile - 30 mM potassium dihydrogenp-
hosphate buffer, pH 2 (30:70 v/v). This method 
was further developed and validated for pharmaco-
kinetics study by Zarghi et al. (9). Talebpour et 
al. recommended an extraction method for 
determination of carvedilol in human plasma 
samples, employing stir bar coated with a film of 
polymethyl metacrylate/ethylenglycol dimethacrylate 
and polymimethyl siloxane in combination with 
liquid desorption, followed by HPLC with ultra-
violet detection (10). Due to specificity of our 
conditions, our analysis required changes in the 
application of already validated HPLC methods. 
The development and the validation of HPLC 
method for carvedilol determination in human 
plasma showed that our method had satisfactory 
characteristics for its application in pharmaco-
kinetic purposes. 
 
Material and methods 
 
Reagents and chemicals 
 
Standard of carvedilol was obtained from 
Sigma-Aldrich (GmbH Germany). HPLC grade 
methanol was supplied by J.T. Baker (Avantor 
Performance Materials, Deventer, The Netherlands). 
Potassium dihydrogen phosphate and potassium 
hydroxide of analytical grade were obtained from 
Merck (Darmstadt, Germany).  
 
HPLC conditions and analysis 
 
The chromatographic analysis was performed 
with an Agilent liquid chromatograph RR HPLC 
1200 (Agilent Technologies, Santa Clara, CA, 
USA) using a fluorescent detector. The analytical 
column was Zorbax SB-C18, 4.6 x 150 mm i.d, 
3.5 µm particle size (Agilent Technologies, Santa 
Clara, CA, USA). Dihydroergocristine mesylate 
was used as the internal standard. The mobile 
phase consisted of 30 mM potassium dihydrogen Carvedilol population pharmacokinetic analysis –  applied validation...                                           Aleksandra Catić-Đorđević et al. 
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phosphate buffer adjusted to pH 2.3 with KOH 
(mobile phase A) and methanol (mobile phase 
B). Gradient elution was performed at a flow rate 
of 1.5 mL/min starting with 48% mobile phase A 
and 52% mobile phase B and keeping that 
composition for the next 3 minutes; from 3 to 3.5 
min gradient changed to 100% mobile phase B 
remaining the same to 6.5 min; from 6.5 to 7.0 
min gradient returned to starting condition 
staying the same till 8 min, which was the end of 
separation.  
Total analysis time was 10 min with the 2 
min of equilibration time. The detection was 
performed fluorometrically with an excitation 
wavelength of 240 nm and an emission wave-
length of 352 nm with the gain of 10, except 
between 2.85 and 3.40 min when it was 12. All 
separations were carried out at the temperature 
of 40 °C. 
 
Standard and calibration solutions 
 
The stock solution of carvedilol was pre-
pared in methanol in a concentration of 1 
mg/mL. Working solutions (10 ng/mL, 100 ng/mL 
and 1000 ng/mL) are diluted with the mobile 
phase A. Calibration solutions for carvedilol were 
prepared by mixing appropriate amounts of 
working solution with blank plasma to obtain 
concentrations of 1, 5, 10, 25, 50 and 100 ng/mL. 
 
Sample preparation for HPLC analysis 
 
For sample preparation 600 µL of cold 
methanol was added to 200 µL of plasma sample. 
This was followed by vortexing and centrifugation 
step at 12000 rpm for 10 minutes at 4°C. 
Afterwards, 550 µL of the supernatant was 
collected and 20 µL was injected into HPLC 
system.  
 
Population pharmacokinetics approach of 
carvedilol 
 
 Population PK analysis of carvedilol is 
carried out using the substance plasma concen-
trations which have been collected over a longer 
period of time from a large number of patients. 
Patients and this data before analysis were divided 
into two groups - group for the population 
mathematical model building as well as group for 
the validation of this model. 
One of the most frequently used approaches 
in population pharmacokinetics (PK) analysis is 
the Nonlinear Modeling of Mixed Effects - 
NONMEM modeling. It is considering two levels of 
effects - fixed effects that define the typical 
population values of PK parameters and random 
effects showing the range of possible values. The 
data required for this type of PK analysis are 
being collected during routine medical control of 
the patients, which is an advantage of this 
approach. Alternatively, processing of the collected 
data is a very complex process that involves 
application of algorithms and software with the 
task to create appropriate mathematical model of 
the chosen system. Regarding choosing the 
software for population analysis, it is necessary 
to know the PK parameters of the tested drug in 
order to have accurate modeling. Procedure for 
the population PK analysis has three primary 
phases. The first phase defines the base model, 
which does not include covariates. This model 
gives us typical values of population pharmaco-
kinetics parameters, such as drug clearance and 
the volume of distribution. Also, it defines 
covariates for interindividual and intraindividual 
variability. The second phase is more complex 
and represents a stepwise process in building 
univariate regression models (11,12). The 
evaluation of statistical significance of every 
variable follows the reduction in the minimum 
value of objective function (MOF) between 
univariate models. The final step of this phase 
includes more restrictive criteria and deletion of 
some variables to get adequate final model. Also, 
it defines error model and mentioned covariate is 
added in the mathematical model (3). When the 
final model is created, which includes significant 
variables, it is necessary to verify the obtained 
model. The third phase is validation of the model. 
Validation group of patients and date set were 
not included in the process of building final 
model. The process of validation confirmed the 
correctness of the obtained model and enables it 
to be used for clinical purposes. 
 
Validation of HPLC procedure for carvedilol  
 
Validation and revalidation of the method 
for quantitative analysis of drugs include deter-
mining the selectivity, accuracy, precision, linearity, 
LOD and LOQ. Validation procedure was carried 
out using the standard of carvedilol.  
The selectivity of HPLC method was 
confirmed by injecting blank samples (from healthy 
volunteers, without carvedilol), spiked samples and 
standard solutions. The linearity of an analytical 
procedure is its ability (within a given range) to 
obtain measured values which are directly propor-
tional to the concentration (amount) of analyte in 
the sample. Linearity of the method was estimated 
by the regression equation.  
The limit of detection (LOD) was measured 
as the lowest amount of carvedilol detected with 
response significantly different from that of a 
blank. The limit of quantification (LOQ) was 
obtained as 3.3 time higher concentration of the 
analyte compared to LOD. 
The accuracy shows deviation of results 
obtained by the chosen method from the 
reference values whereas the precision is the 
closeness of agreement of the results in a 
series of measurements obtained from multiple 
sampling of the same homogeneous sample 
under the prescribed conditions. Precision of 
the method must be defined at three levels: 
repeatability, intermediate precision and repro-Acta Medica Medianae 2013, Vol.52(3)                                  Carvedilol population pharmacokinetic analysis –  applied validation... 
Determined mean precision for three QC 
levels, expressed as relative standard deviation 
(RSD, %), was 3.73%. The accuracy of the method 
was reported as recovery value (R, %). The 
obtained R for low QC, medium QC and high QC 
was 85.33%, 98.22% and 99.10%, respectively.  
The between - day precision was also determined. 
The results for between - day precision showed 
that relative standard deviation was less than 6.0 %. 
ducibility. The precision and accuracy of analytical 
method were investigated using samples containing 
known amounts of the carvedilol. They were 
measured using five replicate injections for three 
quantification levels (QC levels): low QC (4 ng/mL), 
medium QC (40 ng/mL) and high QC (80 ng/mL). 
The range of an analytical procedure is the 
interval between the upper and lower concen-
tration (amounts) of analyte in the sample 
(including these concentrations) for which it has 
been demonstrated that the analytical procedure 
has a suitable level of precision, accuracy and 
linearity (4). Defining the range of the chosen 
measurement, the method can achieve satis-
factory precision, linearity and accuracy, which is 
important for the interpretation of results and PK 
analysis.  
 
Discussion 
 
The results of validation confirmed that the 
chosen HPLC method for carvedilol determination 
in chosen HPLC conditions showed good selectivity 
and wide range of linearity with appropriate 
coefficient of correlation. LOD and LOQ of our 
method have the low values, which provide 
determination of very low concentration of 
carvedilol in the human plasma. Also, relative 
standard deviation and recovery value showed 
satisfactory accuracy and precision of carvedilol 
determination in chosen type of sample. The 
obtained results of the validation confirmed 
validity of data for the application in NONMEM 
software in order to determine population PK 
parameters of carvedilol. 
This study was approved by the Ethics Commi-
ttee of the Faculty of Medicine (No: 01-5413-4). 
 
Results 
 
The HPLC method was tested for selectivity, 
linearity, limit of detection, limit of quantification, 
precision and accuracy.   
The study of selectivity showed that there 
were no interfering substances at the retention 
time of carvedilol (3.12 min). Figure 1 shows 
three chromatograms with the retention times of 
different samples: A – Sample of a carvedilol 
standard, B – Control Sample, C – Real Sample.  
In contemporary clinical practice, population 
PK analysis is often more important than stan-
dard PK approach in setting a mathematical 
model that describes the PK parameters and 
takes into account the variables that have 
particular importance in the drugs pharmaco-
kinetics. Possible variables that can influence 
population PK parameters are sex, body mass, 
dosage, pharmaceutical form, pathophysiological 
state, disease associated with the organism or 
the presence of a specific polymorphism in the 
isoenzyme important for biotransformation of the 
drug. 
The control sample contained the blood of a 
person who did not use carvedilol.  
The linear dependencies were established 
between the response (peak area) and carvedilol 
concentration over the tested range from 1–100 
ng/mL. The regression equation Y=7.2753x + 
10.0277 and correlation coefficient R
2=0.9994 
were achieved.  
The limit of detection and quantification for 
carvedilol (LOD and LOQ) were 0.3 ng/mL and 
1.0 ng/mL, respectively. 
 
 
 
Figure 1. Retention times of carvedilol samples: A - Standard of Carvedilol, B - Control sample, C - Real sample 
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Data, including concentration, sampling 
time and time elapsed since the last taken dose 
need to be modeled appropriately using the 
software, which in the first phase defines the 
basic model of the system. The variables are 
evaluated based on their impact on the value of 
population parameters of a drug, which leads to 
identification of significant variables that are 
included in the final population pharmacokinetic 
model of the PK parameters. 
Results of population pharmacokinetics 
carvedilol aproach suggest that the body weight, 
concomitant therapy with digoxin, and tobacco 
using are the main subjects of his PK variability 
(13,14). The study population consisted of 52 
Caucasian patients with chronic heart failure, 
receiving carvedilol therapy. Population PK 
approach was performed with NONMEM software, 
ADVAN2, TRANS2 procedure for building base 
model. This means one-compartment model with 
first order elimination rate (15). In some PK 
studies the authors showed a significant effect of 
CYP2D6 isoenzyme of in carvedilol clearance 
within Japanese and Caucasian populations (16). 
Owing to its characteristics, population PK 
analysis provides new and important information 
on the product and allows obtaining clinically 
relevant data on the pharmacokinetics of the 
drug in the target study population.  
Identification of demographic, pathophysio-
logical and other factors that may influence the 
population carvedilol PK parameters gives the 
physician the possibility of a more comprehensive 
overview of the patient and better optimization of 
the therapeutical regimen (13,16). 
In conclusion, validation process itself justifies 
the scientific value of established modifications, 
providing the application of the obtained results 
for the purpose of PK analysis. Professional and 
multidisciplinary approach in the interpretation of 
the obtained results provided the access to 
specific population PK parameters of carvedilol. 
Population analysis of carvedilol showed body 
weight, smoking, and the presence of digoxin as 
the variables that may influence the population 
PK parameters of carvedilol in patients with 
congestive heart failure. This specificity provides 
a better therapeutic approach to the patients by 
physician, who always use PK parameters as 
important guidelines in setting up and modifi-
cation of the treatment regimen. 
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VALIDACIJA ANALITIČKE PROCEDURE KARVEDILOLA ZA PRIMENU U 
POPULACIONOJ FARMAKOKINETIČKOJ ANALIZI 
 
Aleksandra Catić-Đorđević, Valentina Nikolić, Slavoljub Živanović, 
Nikola Stefanović, Radmila Veličković-Radovanović 
 
 
Karvedilol je neselektivni beta/alfa-1 blokator koji se koristi za lečenje hipertenzije, 
hronično stabilne angine i nestabilne angine pectoris, kao i ishemijske disfunkcije leve 
komore. Cilj ovog rada bio je da se opiše postupak populacione farmakokinetičke (FK) 
analize karvedilola, kao i da se naglasi važnost validacije analitičke procedure. U 
savremenoj kliničkoj praksi, populaciona FK analiza često je značajnija od prostorne FK 
analize kao standardne procedure. Ona postavlja matematički model koji opisuje FK 
parametre. Pored toga, populacioni FK model uključuje varijable koje imaju poseban značaj 
za farmakokinetiku datog leka, kao što su: pol, telesna težina, doza leka, farmaceutski 
oblik, patofiziološko stanje, pridružene bolesti, kao i prisustvo odgovarajućeg fenotipa 
izoenzima koji učestvuje u metabolizmu leka. Jedan od najčešće korišćenih pristupa u 
populacionoj FK analizi je nelinearno modeliranje mešovitih efekata - NONMEM modeliranje. 
Analitičke metode za prikupljanje podataka od velikog su značaja za pravilno populaciono 
FK modelovanje karvedilola. Visoko-efikasna tečna hromatografija koristi se u kvalitativne i 
kvantitativne svrhe i služi za dobijanje pouzdanih podataka, koji bi bili od koristi u kliničkoj 
praksi za praćenje efikasnosti terapije. Analitičke procedure korišćene u drugim studijama 
nisu mogle biti u potpunosti prenešene na naše istraživanje, već je bilo neophodno izvršiti 
modifikaciju i validaciju metode u cilju korišćenja dobijenih rezultata za populacionu 
farmakokinetičku analizu. Validacija je logičan završni proces u razvoju analitičkog postupka 
i omogućava primenljivost samog postupka. Cilj validacije je da obezbedi konzistentnost 
metode i tačnost rezultata, odnosno da potvrdi izbor analitičke metode za dati uzorak i lek. 
Ova studija je potvrdila važnost korišćenja validiranog analitičkog postupka u populacionoj 
FK analizi karvedilola. Određivanje demografskih, patofizioloških i drugih faktora koji mogu 
da utiču na populacione FK parametre karvedilola daju mogućnost lekaru da sveobuhvatnije 
sagleda bolesnike i omogući optimizaciju terapijskog režima. Acta Medica Medianae 2013; 
52(3):18-24. 
 
Ključne reči: karvedilol, populaciona farmakokinetika, HPLC, validacija 
 
 